FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/676,154	ATTY. DOCKET NO.: M0656.70098US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 9/29/2003	CONFIRMATION NO.: 7775
	APPLICANT: John Landers	
Sheet 1 of 4	GROUP ART UNIT: 1634	EXAMINER: K.D. Salmon

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*A1	US2005/0026212	A1	Sapolsky, R., et al.	2/3/05
	*A2	60/064,358		Wigler, M., et al.	12/30/98
	*A3	4,965,188		Mullis et al.	10/23/90
	*A4	5,501,964		Wigler, M., et al.	3/26/96
	*A5	5,837,832		Chee, M., et al.	11/17/98
	*A6	5,861,242		Chee et al.	1/19/99
	*A7	6,040,166		Erlich, H., et al.	3/21/00
	*A8	6,045,994		Zabeau, M., et al.	4/4/00

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*B1	EP	EP0228075A2		Molecular Diagnostics, Inc.	7/8/87	
	*B2	WO	WO99/23256		Spring Harbor Laboratory	5/14/99	
	*B3	WO	WO90/08821		University of Miami	8/9/90	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*C1	Amselem et al., "Determination of the spectrum of beta-thalassemia genes in Spain by use of dot-blot analysis of amplified beta-globin DNA", Am J Hum Genet. 43(1):95-100 (1988).	
	*C2	Chang et al., "PCR amplification of chromosome-specific DNA isolated from flow cytometry-sorted chromosomes", Genomics.12(2):307-12 (1992).	
	*C3	Crouau-Roy, B., et al., "Analysis of HLA-A/B recombinant families with new polymorphic markers", Hum Immunol. 38(2):132-6 (1993).	
	*C4	Cuppens et al., "Simultaneous screening for 11 mutations in the cystic fibrosis transmembrane conductance regulator gene by multiplex amplification and reverse dot-blot", Mol Cell Probes. 6(1):33-9 (1992).	
	*C5	Danpure et al., "Molecular characterization and clinical use of a polymorphic tandem repeat in an intron of the human alanine:glyoxylate aminotransferase gene", Hum Genet. 94(1):55-64 (1994).	
	*C6	Darnell et al., Molecular Cell Biology. 2nd ed. New York: Scientific American Books, 1990.	
	*C8	DeMarchi et al., "A robotics-assisted procedure for large scale cystic fibrosis mutation analysis", Hum Mutat. (4):281-90 (1994).	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/676,154	ATTY. DOCKET NO.: M0656.70098US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 9/29/2003	CONFIRMATION NO.: 7775
	APPLICANT: John Landers	
Sheet 2 of 4	GROUP ART UNIT: 1634	EXAMINER: K.D. Salmon

	*C7	Dong et al., "Flexible use of high-density oligonucleotide arrays for single-nucleotide polymorphism discovery and validation", Genome Res. 11(8):1418-24 (2001).	
	*C9	Ehsani et al., "Characterization of a new allele of the human ERBB2 gene by allele-specific competition hybridization", Genomics. 15(2):426-9 (1993).	
	*C10	el-Hazmi MA, et al., "DNA polymorphism in the beta-globin gene cluster in Saudi Arabs: relation to severity of sickle cell anaemia", Acta Haematol. 88(2-3):61-6 (1992).	
	*C11	Elion et al., "DNA sequence variation in a negative control region 5' to the beta-globin gene correlates with the phenotypic expression of the beta s mutation", Blood. 79(3):787-92 (1992).	
	*C12	Griffin, H. et al., PCR Technology Current Innovations. Boca Raton: CRC Press, 1994.	
	*C13	Guo et al. "Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports", Nucleic Acids Res. 22(24):5456-65 (1994).	
	*C14	Hacia et al., "Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis", Nat Genet. 14(4):441-7 (1996).	
	*C15	Hejtmancik et al., "In vitro amplification of the alpha 1-antitrypsin gene: application to prenatal diagnosis", Prenat Diagn. 9(3):177-86 (1989).	
	*C16	Hirschhorn et al., "SBE-TAGS: an array-based method for efficient single-nucleotide polymorphism genotyping", Proc Natl Acad Sci U S A. 97(22):12164-9 (2000).	
	*C17	Iitia et al. "Simultaneous detection of two cystic fibrosis alleles using dual-label time-resolved fluorometry", Mol Cell Probes. (6):505-12 (1992).	
	*C18	Jinno et al., "A simple and efficient amplification method of DNA with unknown sequences and its application to microdissection/microcloning", J Biochem (Tokyo). 112(1):75-80 (1992).	
	*C19	Jordan et al., "Genome complexity reduction for SNP genotyping analysis", Proc Natl Acad Sci U S A. 99(5):2942-7 (2002).	
	*C20	Jorgensen et al., "Specific contacts between the bacteriophage T3, T7, and SP6 RNA polymerases and their promoters", 266(1):645-51 (1991).	
	*C21	Kennedy et al., "Large-scale genotyping of complex DNA", (10):1233-7 (2003).	
	*C22	Kwok , "Methods for genotyping single nucleotide polymorphisms", Annu Rev Genomics Hum Genet. 2:235-58 (2001).	
	*C23	Lagerstrom et al., "Capture PCR: efficient amplification of DNA fragments adjacent to a known sequence in human and YAC DNA", PCR Methods Appl. (2):111-9 (1991).	
	*C24	Lander, "Finding similarities and differences among genomes", Nat Genet. 4(1):5-6 (1993)	
	*C25	Lapoumeroulie et al., "A novel sickle cell mutation of yet another origin in Africa: the Cameroon type", Hum Genet. 89(3):333-7 (1992).	
	*C26	Matsuzaki et al., "Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array", Genome Res. 14(3):414-25 (2004).	
	*C27	Mullis et al., The Polymerase Chain Reaction. Boston: Birkhauser, 1994.	
	*C28	Nelson et al., "Genomic mismatch scanning: a new approach to genetic linkage mapping", Nat Genet. 4(1):11-8 (1993).	
	*C29	Ng et al., "Methods for analysis of multiple cystic fibrosis mutations", Hum Genet. 87(5):613-7 (1991).	
	*C30	Prior et al., "A model for molecular screening of newborns: simultaneous detection of Duchenne/Becker muscular dystrophies and cystic fibrosis", Clin Chem. 36(10):1756-9 (1990).	
	*C31	Rapley et al., Molecular Diagnostics. Oxford: Blackwell Scientific Publications, 1993.	
	*C33	Rasmussen et al., "Direct amplification of cDNA inserts from lambda libraries using the cloning-	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/676,154	ATTY. DOCKET NO.: M0656.70098US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 9/29/2003	CONFIRMATION NO.: 7775
	APPLICANT: John Landers	
Sheet 3 of 4	GROUP ART UNIT: 1634	EXAMINER: K.D. Salmon

		adapter as primer for PCR", Nucleic Acids Res. 17(8):3308 (1989).	
	*C32	Saiki et al., "Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes", Proc Natl Acad Sci U S A. 86(16):6230-4 (1989).	
	*C34	Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd ed. Plainview: Cold Spring Harbor Laboratory Press, 1989.	
	*C35	Sapolsky et al., "Mapping genomic library clones using oligonucleotide arrays", Genomics. 33(3):445-56 (1996).	
	*C36	Sarkar et al., "Restriction-site PCR: a direct method of unknown sequence retrieval adjacent to a known locus by using universal primers", PCR Methods Appl. 2(4):318-22 (1993).	
	*C37	Saunders et al., "PCR amplification of DNA microdissected from a single polytene chromosome band: a comparison with conventional microcloning", Nucleic Acids Res. 17(22):9027-37 (1989).	
	*C38	Schlayer et al., "Amplification of unknown DNA sequences by sequence-independent nested polymerase chain reaction using a standardized adaptor without specific primers", J Virol Methods. 38(3):333-41 (1992).	
	*C39	Serre et al., "Nearly 80% of cystic fibrosis heterozygotes and 64% of couples at risk may be detected through a unique screening of four mutations by ASO reverse dot blot", Genomics. 11(4):1149-51 (1991).	
	*C40	Shuber et al., "High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes", Hum Mol Genet. (3):337-47 (1997).	
	*C41	Smith et al., "Ligation-mediated PCR of restriction fragments from large DNA molecules", PCR Methods Appl. 2(1):21-7 (1992).	
	*C42	Sutcliffe et al., "PCR amplification and analysis of yeast artificial chromosomes", Genomics. 13(4):1303-6 (1992).	
	*C43	Suzuki et al., An Introduction to Genetic Analysis. 3rd ed. New York: W.H. Freeman and Company, 1986.	
	*C45	Syvanen et al. "Accessing genetic variation: genotyping single nucleotide polymorphisms", Nat Rev Genet. 2(12):930-42 (2001).	
	*C44	Syvanen et al. "Toward genome-wide SNP genotyping", Nat Genet. 37 Suppl:S5-10 (2005).	
	*C46	Tsuruta et al., "Analysis of the population of human T cell receptor gamma and delta chain variable region subfamilies by reverse dot blot hybridization", J Immunol Methods. 169(1):17-23 (1994).	
	*C47	Unrau et al., "Non-cloning amplification of specific DNA fragments from whole genomic DNA digests using DNA 'indexers'", Gene. 145(2):163-9 (1994).	
	*C48	Welsh et al., "Genomic fingerprinting using arbitrarily primed PCR and a matrix of pairwise combinations of primers", Nucleic Acids Res.19(19):5275-9 (1991).	
	*C49	Patent Interference No. 105,439. Landers Substantive Motion 1 (for judgment of no interference in fact). (Electronically filed, unsigned). September 1, 2006.	
	*C50	Patent Interference No. 105,439. Landers Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). September 1, 2006.	
	*C51	Patent Interference No. 105,439. Landers Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). September 1, 2006.	
	*C52	Patent Interference No. 105,439. Landers Substantive Motion 4 (for judgment based on prior art). (Electronically filed, unsigned). September 1, 2006.	
	*C53	Patent Interference No. 105,439. Landers Substantive Motion 5 (for judgment based on prior art). (Electronically filed, unsigned). September 1, 2006.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/676,154	ATTY. DOCKET NO.: M0656.70098US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 9/29/2003	CONFIRMATION NO.: 7775
	APPLICANT: John Landers	
Sheet 4 of 4	GROUP ART UNIT: 1634	EXAMINER: K.D. Salmon

	*C54	Patent Interference No. 105,439. Landers Substantive Motion 6 (to deny benefit of priority applications). (Electronically filed, unsigned). September 1, 2006.	
	*C55	Patent Interference No. 105,439. Sapolsky Opposition 1 (to Landers Substantive Motion 1). (Electronically filed, unsigned). November 29, 2006	
	*C56	Patent Interference No. 105,439. Sapolsky Opposition 2 (to Landers Substantive Motion 2). (Electronically filed, unsigned). November 29, 2006	
	*C57	Patent Interference No. 105,439. Sapolsky Opposition 3 (to Landers Substantive Motion 3). (Electronically filed, unsigned). November 29, 2006	
	*C58	Patent Interference No. 105,439. Sapolsky Opposition 4 (to Landers Substantive Motion 4). (Electronically filed, unsigned). November 29, 2006	
	*C59	Patent Interference No. 105,439. Sapolsky Opposition 5 (to Landers Substantive Motion 5). (Electronically filed, unsigned). November 29, 2006	
	*C60	Patent Interference No. 105,439. Sapolsky Opposition 6 (to Landers Substantive Motion 6). (Electronically filed, unsigned). November 29, 2006	
	*C61	Patent Interference No. 105,439. Landers Reply 1 (to Sapolsky Opposition 1). (Electronically filed, unsigned). January 12, 2007	
	*C62	Patent Interference No. 105,439. Landers Reply 2 (to Sapolsky Opposition 2). (Electronically filed, unsigned). January 12, 2007	
	*C63	Patent Interference No. 105,439. Landers Reply 3 (to Sapolsky Opposition 3). (Electronically filed, unsigned). January 12, 2007	
	*C64	Patent Interference No. 105,439. Landers Reply 4 (to Sapolsky Opposition 4). (Electronically filed, unsigned). January 12, 2007	
	*C65	Patent Interference No. 105,439. Landers Reply 5 (to Sapolsky Opposition 5). (Electronically filed, unsigned). January 12, 2007	
	*C66	Patent Interference No. 105,439. Landers Reply 6 (to Sapolsky Opposition 6). (Electronically filed, unsigned). January 12, 2007	
	*C67	Patent Interference No. 105,439. Sapolsky Contingent Responsive Motion 1 (to add new Claims 58-62). (Electronically filed, unsigned). October 13, 2006	
	*C68	Patent Interference No. 105,439. Landers Opposition 1 (to Sapolsky Contingent Responsive Motion 1). (Electronically filed, unsigned). November 29, 2006	
	*C69	Patent Interference No. 105,439. Sapolsky Reply 1 (to Landers Opposition 1). (Electronically filed, unsigned). January 12, 2007	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.